Single hydrogel injection linked to 12-month pain reduction in 18-dog elbow OA studyThree JAK inhibitors and two monoclonal antibodies now approved for canine atopic dermatitisAnti-IL-23 biologic hit positive results in a 19-dog IBD pilot trialNew veterinary graduates have clinical foundations but lack the volume fluency practices expectBoard-certified internist says DVMs need to shape AI tools before consumer tech companies doBrakke Consulting framed fuel costs as a pass-through in its October newsletterAVMA greenlights Maryland Eastern Shore vet school, first public HBCU programAntech Accuplex showed higher Ehrlichia sensitivity than IDEXX SNAP 4Dx Plus in a JAVMA studySingle hydrogel injection linked to 12-month pain reduction in 18-dog elbow OA studyThree JAK inhibitors and two monoclonal antibodies now approved for canine atopic dermatitisAnti-IL-23 biologic hit positive results in a 19-dog IBD pilot trialNew veterinary graduates have clinical foundations but lack the volume fluency practices expectBoard-certified internist says DVMs need to shape AI tools before consumer tech companies doBrakke Consulting framed fuel costs as a pass-through in its October newsletterAVMA greenlights Maryland Eastern Shore vet school, first public HBCU programAntech Accuplex showed higher Ehrlichia sensitivity than IDEXX SNAP 4Dx Plus in a JAVMA study
The Exam RoomBy The VeterinaryPracticeNow Desk3 min readOctober 27, 2026
Single hydrogel injection linked to 12-month pain reduction in 18-dog elbow OA study
A prospective single-site study tracked 16 dogs through 12 months after a single intra-articular injection, reporting significant improvements in all pain and function measures.
A prospective single-site study found that a single intra-articular injection of 2.5% polyacrylamide hydrogel was associated with sustained improvements in pain and function measures through 12 months in dogs with elbow osteoarthritis. The study enrolled 18 client-owned dogs and tracked outcomes at multiple intervals after injection.
What the study found
Dogs with CT-confirmed elbow OA received unilateral or bilateral intra-articular injections of 1 mL of 2.5% injectable polyacrylamide hydrogel (iPAAG). Sixteen of the 18 dogs completed the study. According to the study, "there were significant improvements in all measures between baseline and 3 to 12 months" after injection. The measures tracked included pain severity, pain interference, composite pain scale scores, numerical rating, elbow range of motion, thoracic limb girth, and joint effusion. The study reported "minimal, self-limiting adverse events and no clinically significant changes" in complete blood count or serum biochemistry at 3 months.
How the study was built
This was a prospective single-site clinical study that enrolled dogs between October 2023 and October 2024. Dogs had elbow OA confirmed by CT before enrollment. The study conducted assessments at baseline and at 2 weeks, 1 month, 3 months, 6 months, and 12 months after injection, according to the methods. Blood work was done at baseline and 3 months. The study had no control group, so it cannot isolate the hydrogel's effect from placebo, natural disease progression, or concurrent treatments. The small sample size (18 dogs enrolled, 16 completed) limits the precision of the effect estimates and the ability to detect rare adverse events.
The number, and its error bars
The study reported overall effect sizes for each measure. Pain severity had an effect size of 0.44, pain interference 0.53, the composite pain scale 0.69, numerical rating 0.63, elbow flexion 0.31, elbow extension 0.64, thoracic limb girth 0.53, and joint effusion 0.64. The abstract does not provide confidence intervals, p-values, raw score changes, or the specific effect size metric used for these values.
What the authors say it cannot tell you
The authors state that "study limitations included a small sample size and lack of control group." They also note that "further research is warranted to evaluate histological effects" of the hydrogel.
Who paid for it
The source does not state who funded the study or whether the authors declared conflicts of interest.
What this means for your practice
VeterinaryPracticeNow's read, not the study's. Everything in this section is our editorial interpretation for practice owners. The study does not claim any of it.
A year-long effect from a single injection changes the economics of elbow OA management. Chronic NSAID therapy carries monitoring costs, client compliance risk, and the recurring-refill model. An injectable with durable effect shifts the revenue model from monthly refills to a one-time procedure fee and may lower the follow-up load. The trade-off depends on your case mix and whether clients are already pushing back on long-term NSAID costs or monitoring bloodwork.
The lack of a control group means you cannot separate the hydrogel's effect from placebo or natural fluctuation in OA pain, which matters when you are explaining the evidence base to a client who asks. The study does not report cost, so you cannot yet run the comparison against your current OA protocol or compare it to corticosteroid or hyaluronic acid injectables you may already stock. A rare adverse event could still surface in broader use.
For the associate DVM, this is a tool that buys time before surgical referral and may lower the number of NSAID-monitoring conversations you have with cost-sensitive clients. For the owner-DVM, it is a potential differentiator if competitors are NSAID-only, but you will need to price it in a way that covers the product cost and the injection time without pricing out the clients who would have stayed on oral therapy.
Get the next issue in your inbox. Free, weekly, no fluff.
